These improvements in cardiovascular risk markers, combined with enhanced insulin sensitivity and glucose metabolism, suggest tesofensine may provide comprehensive metabolic benefits for obese individuals with comorbid metabolic conditions
In the gastrointestinal tract, GHK-Cu enhances epithelial proliferation, reduces oxidative stress, and modulates inflammatory cytokines
Its global incidence amounts to millions of individuals [1], possibly 1% of populations, and even 20 years ago, its cost represented some 1% of the NHS budget, with all these numbers on a rising trend [6,7,8,9], albeit with large regional differences of incidence and/or reporting (e.g., South Asia is said to be 12 lower than North America [10])
Open communication with healthcare providers, insurance companies, and pharmaceutical companies is crucial for patients to understand their coverage options, explore potential cost-saving strategies, and access available resources to help manage their out-of-pocket expenses